|
271 Companies |
|
374 Products |
|
374 Products |
|
160 Mechanisms of Action |
|
34 Trials |
|
5514 News |
|
| «12...5859606162636465666768...110111» |
- | ONT-10 / Seagen
New P1 trial, Metastases: Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer (clinicaltrials.gov) - Oct 22, 2014
P1, N=42, Not yet recruiting, Sponsor: Oncothyreon Inc.
- || Visanne (dienogest) / Mochida, Bayer
Enrollment closed, Trial primary completion date, HEOR: DIVA: Daily Practice Treatment and Influence of Visanne on the Patient Assessment of Quality of Life (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=3005, Active, not recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2014
- |||| Trial completion: EURAS-IUD: European Active Surveillance Study for Intrauterine Devices (clinicaltrials.gov) - Oct 22, 2014
P4, N=63194, Completed, Sponsor: Center for Epidemiology and Health Research, Germany
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2014 Active, not recruiting --> Completed
- imatinib / Generic mfg., gemcitabine / Generic mfg.
Enrollment change: Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer (clinicaltrials.gov) - Oct 22, 2014
P2, N=8, Completed, Sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine
Active, not recruiting --> Completed N=60 --> 8
- clomifene citrate / Generic mfg.
Clinical: Predictors of Ovarian Response During Clomiphene Citrate Ovulation Induction in Patients With Polycystic Ovary Syndrome (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=150, Completed, Sponsor: Menoufia Obstetrics and Gynecology Group
- Enrollment open, Trial initiation date, Trial primary completion date: KCCP: The Kilimanjaro Cervical Screening Project (clinicaltrials.gov) - Oct 22, 2014
P=N/A, N=300, Recruiting, Sponsor: Queen's University
N=60 --> 8 Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> May 2014 | Trial primary completion date: Apr 2014 --> Mar 2015
- || Trial initiation date: Evaluation of Enhanced Syphilis Screening Among HIV-positive Men (clinicaltrials.gov) - Oct 20, 2014
P=N/A, N=3131, Not yet recruiting, Sponsor: Ontario HIV Treatment Network
Not yet recruiting --> Recruiting | Initiation date: Jan 2014 --> May 2014 | Trial primary completion date: Apr 2014 --> Mar 2015 Initiation date: Jul 2014 --> Dec 2014
- Preclinical: Correlating In Vitro Fertilization Outcomes After Euploid Blastocyst Transfer With Sperm DNA Fragmentation (clinicaltrials.gov) - Oct 20, 2014
P=N/A, N=600, Enrolling by invitation, Sponsor: Reproductive Medicine Associates of New Jersey
- Trial primary completion date: Screening for Endometrial Abnormalities in Overweight and Obese Women (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=300, Recruiting, Sponsor: St. Luke's-Roosevelt Hospital Center
Initiation date: Jul 2014 --> Dec 2014 Trial primary completion date: Sep 2014 --> Aug 2015
- Gralise (gabapentin) / Alvogen
Trial primary completion date: A Trial of Gabapentin in Vulvodynia: Biological Correlates of Response (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=120, Recruiting, Sponsor: University of Tennessee
Trial primary completion date: Sep 2014 --> Aug 2015 Trial primary completion date: Mar 2015 --> Mar 2016
- | New P1/2 trial: Early Embryo Cleavage And Multiple Pregnancies After ICSI (clinicaltrials.gov) - Oct 17, 2014
P1/2, N=193, Completed, Sponsor: Al-Azhar University
- progesterone / Generic mfg.
Enrollment open: A RCT Comparing Spontaneous Natural Cycles and Human Chorionic Gonadotrophin-induced Natural Cycles in FET (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=300, Recruiting, Sponsor: The University of Hong Kong
Trial primary completion date: Mar 2015 --> Mar 2016 Not yet recruiting --> Recruiting
- Trial completion: OV-AP-ICG-IV: Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients (clinicaltrials.gov) - Oct 17, 2014
P1/2, N=10, Completed, Sponsor: Jules Bordet Institute
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial primary completion date: PapU-APV: Research for Papillomavirus as the Examination of Orientation in the Organized Screening of the Cervical Cancer (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=460, Recruiting, Sponsor: University Hospital, Brest
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Oct 2015
- lidocaine 5% / Generic mfg.
Trial primary completion date: Provoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study (clinicaltrials.gov) - Oct 17, 2014
P1, N=30, Recruiting, Sponsor: Oregon College of Oriental Medicine
Trial primary completion date: Apr 2015 --> Oct 2015 Trial primary completion date: Mar 2015 --> Jun 2015
- |||| Bravelle (urofollitropin) / Ferring
Trial primary completion date, Head-to-Head: Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females (clinicaltrials.gov) - Oct 17, 2014
P3, N=180, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Mar 2015 --> Jun 2015 Trial primary completion date: Sep 2014 --> Feb 2015
- Trial primary completion date: A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women (clinicaltrials.gov) - Oct 17, 2014
P1, N=1208, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Sep 2014 --> Feb 2015 Trial primary completion date: Jun 2014 --> Jun 2015
- ||||| Bravelle (urofollitropin) / Ferring
Enrollment change, Trial primary completion date, Head-to-Head: Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program (clinicaltrials.gov) - Oct 17, 2014
P3, N=264, Recruiting, Sponsor: Ferring Pharmaceuticals
Trial primary completion date: Jun 2014 --> Jun 2015 N=200 --> 264 | Trial primary completion date: Sep 2014 --> Feb 2015
- Clinical: Response of VEGF and AT-II to HCG in PCOS (clinicaltrials.gov) - Oct 17, 2014
P0, N=60, Completed, Sponsor: Nanjing University School of Medicine
- Clinical: Primary Care Providers' Views and Understanding of Current Recommended Guidelines for Cervical Cancer Screening (clinicaltrials.gov) - Oct 17, 2014
P=N/A, N=1000, Not yet recruiting, Sponsor: University of Southern California
- ||||| Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date: A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer (clinicaltrials.gov) - Oct 17, 2014
P3, N=1043, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=200 --> 264 | Trial primary completion date: Sep 2014 --> Feb 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Dec 2014
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg.
Trial completion, Trial primary completion date, Combination therapy: A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma (clinicaltrials.gov) - Oct 17, 2014
P2, N=90, Completed, Sponsor: Jules Bordet Institute
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Dec 2014 Active, not recruiting --> Completed | Trial primary completion date: Oct 2013 --> May 2014
- | motolimod (VTX 2337) / BMS
Trial completion, Enrollment change, Trial primary completion date, Combination therapy: TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer (clinicaltrials.gov) - Oct 17, 2014
P1, N=20, Completed, Sponsor: Gynecologic Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Oct 2013 --> May 2014 Active, not recruiting --> Completed | N=36 --> 20 | Trial primary completion date: Feb 2015 --> Jul 2014
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
HEOR, Real-world evidence, BRCA Biomarker, Real-world: OSCA - Olaparib Standard of CAre Study (clinicaltrials.gov) - Oct 15, 2014
P=N/A, N=2000, Not yet recruiting, Sponsor: AstraZeneca
- birinapant (IGM-9427) / IGM Biosciences, conatumumab (AMG 655) / Amgen
Trial primary completion date, Combination therapy: Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer (clinicaltrials.gov) - Oct 15, 2014
P1, N=40, Recruiting, Sponsor: TetraLogic Pharmaceuticals
Active, not recruiting --> Completed | N=36 --> 20 | Trial primary completion date: Feb 2015 --> Jul 2014 Trial primary completion date: Sep 2014 --> Apr 2015
- STM-434 / Atara
New P1 trial, Combination therapy, Metastases: Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors (clinicaltrials.gov) - Oct 15, 2014
P1, N=66, Recruiting, Sponsor: Santa Maria Biotherapeutics
- |||| metformin hydrochloride extended release / Generic mfg.
Trial primary completion date: Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS) (clinicaltrials.gov) - Oct 11, 2014
P3, N=124, Recruiting, Sponsor: Dexa Medica Group
Trial primary completion date: Sep 2014 --> Apr 2015 Trial primary completion date: Dec 2014 --> Jan 2016
- doxycycline / Generic mfg.
Clinical: DPMSM: Efficacy of Doxycycline Prophylaxis to Reduce Syphilis in High-Risk, HIV-Positive MSM (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=30, Completed, Sponsor: Los Angeles LGBT Center
- Trial completion, Enrollment change: Single-step Versus Sequential Media in Preimplantation Embryo Development and Pregnancy Rates (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=131, Completed, Sponsor: Eugonia
Trial primary completion date: Dec 2014 --> Jan 2016 Recruiting --> Completed | N=200 --> 131
- Trial primary completion date: FOLFIV: Impact of Folates in the Care of the Male Infertility (clinicaltrials.gov) - Oct 11, 2014
P3, N=368, Recruiting, Sponsor: Assistance Publique - H
Recruiting --> Completed | N=200 --> 131 Trial primary completion date: Dec 2014 --> Jun 2016
- Enrollment closed: Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors (clinicaltrials.gov) - Oct 11, 2014
P=N/A, N=75, Active, not recruiting, Sponsor: Ohio State University Comprehensive Cancer Center
Trial primary completion date: Dec 2014 --> Jun 2016 Recruiting --> Active, not recruiting
- | paclitaxel / Generic mfg.
Trial completion, Metastases: S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission (clinicaltrials.gov) - Oct 11, 2014
P3, N=308, Completed, Sponsor: Southwest Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | zoliflodacin (ETX0914) / Entasis Therap, Global Antibiotic Research and Development Partnership
New P2 trial: Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea (clinicaltrials.gov) - Oct 10, 2014
P2, N=180, Not yet recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- || Enrollment closed: Stress Reduction for Overweight or Obese Women Either With Polycystic Ovary Syndrome (PCOS) or Without PCOS (Non-PCOS) (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=98, Active, not recruiting, Sponsor: Milton S. Hershey Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Trial completion, Enrollment change, Trial primary completion date: Office Hysteroscopy and Endometrial Snip Improve Intrauterine Insemination Outcome (clinicaltrials.gov) - Oct 10, 2014
P3, N=200, Completed, Sponsor: Cairo University
Recruiting --> Active, not recruiting Recruiting --> Completed | N=120 --> 200 | Trial primary completion date: Oct 2012 --> Sep 2014
- ||| indomethacin / Generic mfg.
Trial completion, Trial primary completion date: RECIA: Multifactorial Approach to Emergent Cerclage (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=53, Completed, Sponsor: Northwestern University
Recruiting --> Completed | N=120 --> 200 | Trial primary completion date: Oct 2012 --> Sep 2014 Recruiting --> Completed | Trial primary completion date: Jul 2011 --> Mar 2013
- ||| Trial completion, Enrollment change: FEMIN: The Female Health Dietary Intervention Study (clinicaltrials.gov) - Oct 10, 2014
P=N/A, N=61, Completed, Sponsor: The Hospital of Vestfold
Recruiting --> Completed | Trial primary completion date: Jul 2011 --> Mar 2013 Active, not recruiting --> Completed | N=190 --> 61
- || trebananib (AMG 386) / Amgen
Trial primary completion date, Combination therapy, Metastases: AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR (clinicaltrials.gov) - Oct 10, 2014
P1, N=103, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed | N=190 --> 61 Trial primary completion date: Sep 2014 --> Dec 2014
- | New P1 trial: Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (clinicaltrials.gov) - Oct 10, 2014
P1, N=48, Recruiting, Sponsor: Dr. Reddy's Laboratories Limited
- metformin / Generic mfg.
Enrollment open: A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women (clinicaltrials.gov) - Oct 10, 2014
P2, N=40, Recruiting, Sponsor: University of Arkansas
Trial primary completion date: Sep 2014 --> Dec 2014 Active, not recruiting --> Recruiting
- || Talzenna (talazoparib) / Pfizer
Enrollment closed, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Oct 10, 2014
P1, N=85, Active, not recruiting, Sponsor: BioMarin Pharmaceutical
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- Trial completion, Enrollment change, Trial primary completion date, Metastases: Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (clinicaltrials.gov) - Oct 10, 2014
P1, N=8, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=18 --> 8 | Trial primary completion date: Mar 2015 --> Oct 2014
- Trial completion, Enrollment change, Trial primary completion date: Leveraging Technology as a Clinician Extender to Screen Culturally Diverse Young Women for Chlamydia (clinicaltrials.gov) - Oct 4, 2014
P=N/A, N=346, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed | N=18 --> 8 | Trial primary completion date: Mar 2015 --> Oct 2014 Recruiting --> Completed | N=1000 --> 346 | Trial primary completion date: Jul 2010 --> Jul 2012
- Trial completion, Enrollment change: Population-Based Patient-Centric Care: Comprehensive Preventive Cancer Screening Using Health IT (clinicaltrials.gov) - Oct 4, 2014
P=N/A, N=103870, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | N=1000 --> 346 | Trial primary completion date: Jul 2010 --> Jul 2012 Active, not recruiting --> Completed | N=25000 --> 103870
- || Trial primary completion date: Pregnancy, Childbirth Intentions and Outcomes Under Sexual Pain (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=210, Recruiting, Sponsor: University of British Columbia
Active, not recruiting --> Completed | N=25000 --> 103870 Trial primary completion date: Feb 2014 --> Aug 2015
- ||||| progesterone / Generic mfg.
New P4 trial, Head-to-Head: Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer (clinicaltrials.gov) - Oct 2, 2014
P4, N=1170, Not yet recruiting, Sponsor: Shady Grove Fertility Reproductive Science Center
- | Elonva (corifollitropin alfa) / Organon
New P4 trial: MANCOR: Corifollitropin Alfa Versus Daily rFSH in the Controlled Ovarian Stimulation of Poor Responders (clinicaltrials.gov) - Oct 2, 2014
P4, N=60, Recruiting, Sponsor: IVI Sevilla
- |||||||||| New P3 trial: Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women (clinicaltrials.gov) - Oct 2, 2014
P3, N=700, Recruiting, Sponsor: TherapeuticsMD
- alvocidib (DSP-2033) / Sumitomo Pharma
Trial primary completion date: Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors (clinicaltrials.gov) - Oct 2, 2014
P2, N=50, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2014 --> Aug 2015 Trial primary completion date: Aug 2014 --> Jan 2015
- Clinical: Cervical Cancer Screening in HIV Positive and Negative Women in Cambodia (clinicaltrials.gov) - Oct 2, 2014
P=N/A, N=1000, Not yet recruiting, Sponsor: Sihanouk Hospital Center of HOPE